Primary bilateral macronodular adrenal hyperplasia: A series of 32 cases and literature review.

[1]  M. Marazuela,et al.  Cushing´s syndrome due to bilateral adrenal cortical disease: Bilateral macronodular adrenal cortical disease and bilateral micronodular adrenal cortical disease , 2022, Frontiers in Endocrinology.

[2]  J. Bertherat,et al.  Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease , 2022, Nature Reviews Endocrinology.

[3]  E. Pascual-Corrales,et al.  Prevalence and phenotype of primary bilateral macronodular adrenal hyperplasia with autonomous cortisol secretion: a study of 98 patients. , 2022, Revista clinica espanola.

[4]  C. Stratakis,et al.  Genetic Alterations in Benign Adrenal Tumors , 2022, Biomedicines.

[5]  A. Tabarin,et al.  Identification of predictive criteria for pathogenic variants of the Primary Bilateral Macronodular Adrenal Hyperplasia gene ARMC5 in 352 unselected patients. , 2022, European journal of endocrinology.

[6]  Han-Zhong Li,et al.  A 30-year single-center experience of unilateral adrenalectomy for primary bilateral macronodular adrenal hyperplasia. , 2022, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[7]  M. C. Fragoso,et al.  An Overview of the Heterogeneous Causes of Cushing Syndrome Resulting From Primary Macronodular Adrenal Hyperplasia (PMAH) , 2022, Journal of the Endocrine Society.

[8]  M. Papotti,et al.  Overview of the 2022 WHO Classification of Adrenal Cortical Tumors , 2022, Endocrine Pathology.

[9]  E. Letouzé,et al.  KDM1A inactivation causes hereditary food-dependent Cushing syndrome. , 2021, Genetics in medicine : official journal of the American College of Medical Genetics.

[10]  I. Chiodini,et al.  Management and Medical Therapy of Mild Hypercortisolism , 2021, International journal of molecular sciences.

[11]  P. Chanson,et al.  Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. , 2021, The lancet. Diabetes & endocrinology.

[12]  C. Stratakis,et al.  Molecular Genetic and Genomic Alterations in Cushing’s Syndrome and Primary Aldosteronism , 2021, Frontiers in Endocrinology.

[13]  A. Lacroix,et al.  Role of unilateral adrenalectomy in bilateral adrenal hyperplasias with Cushing's syndrome. , 2021, Best practice & research. Clinical endocrinology & metabolism.

[14]  R. Ferrigno,et al.  Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials , 2020, Frontiers in Endocrinology.

[15]  Y. Aso,et al.  Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report. , 2020, European journal of endocrinology.

[16]  A. Grangeia,et al.  ARMC5 Primary Bilateral Macronodular Adrenal Hyperplasia Associated with a Meningioma: A Family Report , 2020, Case reports in endocrinology.

[17]  M. Srougi,et al.  A New Insight into the Surgical Treatment of Primary Macronodular Adrenal Hyperplasia , 2020, Journal of the Endocrine Society.

[18]  Tomoaki Tanaka,et al.  A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease. , 2020, Endocrine journal.

[19]  M. Araujo-Castro,et al.  Practical guide on the initial evaluation, follow-up, and treatment of adrenal incidentalomas Adrenal Diseases Group of the Spanish Society of Endocrinology and Nutrition. , 2020, Endocrinologia, diabetes y nutricion.

[20]  F. Faucz,et al.  Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia. , 2020, Endocrine-related cancer.

[21]  J. Bertherat,et al.  Update of Genetic and Molecular Causes of Adrenocortical Hyperplasias Causing Cushing Syndrome , 2020, Hormone and Metabolic Research.

[22]  G. Occhi,et al.  Allelic Variants of ARMC5 in Patients With Adrenal Incidentalomas and in Patients With Cushing's Syndrome Associated With Bilateral Adrenal Nodules , 2020, Frontiers in Endocrinology.

[23]  A. Lacroix,et al.  Adrenocortical hyperplasia: A multifaceted disease. , 2020, Best practice & research. Clinical endocrinology & metabolism.

[24]  S. Tsagarakis,et al.  Diagnosis and management of primary bilateral macronodular adrenal hyperplasia , 2019, Endocrine-related cancer.

[25]  N. Kanamoto,et al.  ARMC5 Alterations in Primary Macronodular Adrenal Hyperplasia (PMAH) and the Clinical State of Variant Carriers , 2019, Journal of the Endocrine Society.

[26]  F. Beuschlein,et al.  Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. , 2019, Journal of Clinical Endocrinology and Metabolism.

[27]  A. Peters,et al.  Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH) , 2019, The Journal of clinical endocrinology and metabolism.

[28]  S. Izadmehr,et al.  MIFEPRISTONE TREATMENT FOR MILD AUTONOMOUS CORTISOL SECRETION DUE TO ADRENAL ADENOMAS: A PILOT STUDY. , 2019, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[29]  M. Marazuela,et al.  Autonomous cortisol secretion in adrenal incidentalomas , 2019, Endocrine.

[30]  O. Dekkers,et al.  Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis , 2018, Pituitary.

[31]  A. Lacroix,et al.  Aberrant G-protein coupled hormone receptor in adrenal diseases. , 2018, Best practice & research. Clinical endocrinology & metabolism.

[32]  M. Debono,et al.  Resetting the Abnormal Circadian Cortisol Rhythm in Adrenal Incidentaloma Patients With Mild Autonomous Cortisol Secretion , 2017, The Journal of clinical endocrinology and metabolism.

[33]  E. Menis,et al.  A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype , 2017, Endocrine.

[34]  Fares Alahdab,et al.  THERAPY OF ENDOCRINE DISEASE: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: a systematic review and meta-analysis. , 2016, European journal of endocrinology.

[35]  J. Deeks,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis , 2016, European journal of endocrinology.

[36]  A. Tabarin,et al.  Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. , 2016, European journal of endocrinology.

[37]  F. Sebag,et al.  Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism? , 2016, Endocrine-related cancer.

[38]  P. Awadalla,et al.  ARMC5 mutations in a large French-Canadian family with cortisol-secreting β-adrenergic/vasopressin responsive bilateral macronodular adrenal hyperplasia. , 2016, European journal of endocrinology.

[39]  A. Tabarin,et al.  Unilateral Adrenalectomy as a First-Line Treatment of Cushing's Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. , 2015, The Journal of clinical endocrinology and metabolism.

[40]  A. Lacroix,et al.  Multiple aberrant hormone receptors in Cushing's syndrome. , 2015, European journal of endocrinology.

[41]  A. Fassina,et al.  An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: a single‐centre experience , 2015, Clinical endocrinology.

[42]  C. Stratakis,et al.  Germline PRKACA amplification leads to Cushing syndrome caused by 3 adrenocortical pathologic phenotypes. , 2015, Human pathology.

[43]  P. May,et al.  Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma. , 2015, The Journal of clinical endocrinology and metabolism.

[44]  S. Comte-Perret,et al.  Long-term low-dose ketoconazole treatment in bilateral macronodular adrenal hyperplasia , 2014, Endocrinology, diabetes & metabolism case reports.

[45]  P. Hamet,et al.  ARMC5 mutations are a frequent cause of primary macronodular adrenal Hyperplasia. , 2014, The Journal of clinical endocrinology and metabolism.

[46]  F. Faucz,et al.  Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. , 2014, The Journal of clinical endocrinology and metabolism.

[47]  A. Tabarin,et al.  Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. , 2013, The New England journal of medicine.

[48]  M. Sibony,et al.  ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. , 2013, The New England journal of medicine.

[49]  C. V. van Eijck,et al.  ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase , 2013, Orphanet Journal of Rare Diseases.

[50]  R. Eastell,et al.  Mifepristone Reduces Insulin Resistance in Patient Volunteers with Adrenal Incidentalomas That Secrete Low Levels of Cortisol: A Pilot Study , 2013, PloS one.

[51]  W. Linehan,et al.  Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer. , 2013, The Journal of urology.

[52]  A. Zaheer,et al.  Adrenal masses: contemporary imaging characterization. , 2013, Journal of computer assisted tomography.

[53]  J. Bertherat,et al.  Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors. , 2012, The Journal of clinical endocrinology and metabolism.

[54]  F. Faucz,et al.  Identification of novel genetic variants in phosphodiesterase 8B ( PDE8B ), a cAMP‐specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours , 2012, Clinical endocrinology.

[55]  T. L. Mazzuco,et al.  Genetic aspects of adrenocortical tumours and hyperplasias , 2012, Clinical Endocrinology.

[56]  A. Tabarin,et al.  Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database. , 2012, European journal of endocrinology.

[57]  C. Cheadle,et al.  Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations. , 2012, The Journal of clinical endocrinology and metabolism.

[58]  R. Thakker,et al.  Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[59]  T. Stratigou,et al.  Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas , 2011, Endocrine.

[60]  F. Nwariaku,et al.  Clinical, biochemical, and molecular characterization of macronodular adrenocortical hyperplasia of the zona reticularis: a new syndrome. , 2010, The Journal of clinical endocrinology and metabolism.

[61]  J. Bertherat,et al.  Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome. , 2010, European journal of endocrinology.

[62]  P. Hamet,et al.  Aberrant G‐protein coupled receptor expression in relation to adrenocortical overfunction , 2009, Clinical endocrinology.

[63]  A. Lacroix.  ACTH-independent macronodular adrenal hyperplasia. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[64]  M. Collins,et al.  McCune-Albright syndrome , 2008, Orphanet journal of rare diseases.

[65]  K. Klose,et al.  Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. , 2008, European journal of endocrinology.

[66]  V. Montori,et al.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[67]  C. Stratakis.  Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome). , 2008, Endocrine development.

[68]  Sihoon Lee,et al.  Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH‐independent macronodular adrenal hyperplasia , 2005, Clinical endocrinology.

[69]  L. Noon,et al.  Constitutive activation of the human ACTH receptor resulting from a synergistic interaction between two naturally occurring missense mutations in the MC2R gene , 2004, Molecular and Cellular Endocrinology.

[70]  A. Latronico,et al.  Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. , 2003, The Journal of clinical endocrinology and metabolism.

[71]  P. Hamet,et al.  Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. , 2001, Endocrine reviews.

[72]  R. Reznek,et al.  Adrenal masses are associated with familial adenomatous polyposis , 2000, Diseases of the colon and rectum.

[73]  P. Hamet,et al.  Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing's syndrome? , 2000, The Journal of clinical endocrinology and metabolism.

[74]  N. Shimizu.  [Cushing's disease]. , 1993, Nihon rinsho. Japanese journal of clinical medicine.